Trending stocks today
Masimo (MASI-Q)
NASDAQ:MASI
135.99
0.75
(0.55%) 1d
Financials
Technical Analysis
This summary was created by AI, based on 1 opinions in the last 12 months.
Experts have expressed concern over Masimo's negative momentum and poor guidance from management. The company's decline in both sales and estimates, as well as reduced guidance, have contributed to these worries. Masimo's valuation metrics, such as forward sales and growth estimates, have been considered weak relative to its peers. Overall, experts are not convinced of Masimo's current performance and would prefer to see a shift in momentum with sales orders before becoming more comfortable with the stock.
$100.270
Unknown
- «
- ‹
- 1
- ›
- »
Masimo(MASI-Q) Rating
Ranking : 3 out of 5
Bullish - Buy Signals / Votes : 0
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 1
Total Signals / Votes : 1
Masimo(MASI-Q) Frequently Asked Questions
What is Masimo stock symbol?
Masimo is a American stock, trading under the symbol MASI-Q on the NASDAQ (MASI). It is usually referred to as NASDAQ:MASI or MASI-Q
Is Masimo a buy or a sell?
In the last year, 1 stock analyst published opinions about MASI-Q. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Masimo.
Is Masimo a good investment or a top pick?
Masimo was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Masimo.
Why is Masimo stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Masimo worth watching?
In the last year, there was no coverage of Masimo published on Stockchase.
What is Masimo stock price?
On 2024-04-26, Masimo (MASI-Q) stock closed at a price of $135.99.
MASI is a $5.4B company, which has declined ~32% year-to-date and 31% on a one-year basis. It missed on both sales and estimates in its recent quarter, and management noted it was displeased with results. Reduced guidance was led by assumptions of impatient volumes not returning to levels that management expected and it is not receiving some of the new large orders it anticipated. It trades at a 2.5X forward sales and 27.8X forward earnings multiple, which are both below its 10-year average. Relative to some of its peers, it trades at a cheaper P/E and price-to-sales valuation, but its forward sales and growth estimates are also weak relative to peers. We are not big fans of its negative momentum and poor guidance from management - we would prefer to see a shift in momentum with sales orders before getting more comfortable with the name.
Unlock Premium - Try 5i Free